Naphthylenyl compounds for long-acting injectable compositions and related methods
The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
1. A compound of Formula Ib:
or a pharmaceutically acceptable salt thereof;
wherein:
both R groups, always being the same, are selected from hydrogen, halogen, unsubstituted C 1 -C 4 alkyl, unsubstituted C 1 -C 4 alkoxy, or unsubstituted C 1 -C 4 alkylcarbonyloxy;
both values of z, always being the same, are 1, 2, 3, or 4; and
wherein the R groups are bound with points of attachment selected from the 1 and 1′ positions, the 3 and 3′ positions, or the 4 and 4′ positions.
2. The compound of claim 1 , wherein the R groups are bound with points of attachment at the 1 and 1′ positions.
3. The compound of claim 1 , wherein the R groups are bound with points of attachment at the 3 and 3′ positions.
4. The compound of claim 1 , wherein the R groups are bound with points of attachment at the 4 and 4′ positions.
5. The compound of claim 1 , wherein both R groups are hydrogen.
6. The compound of claim 1 , wherein both R groups are halogen.
7. The compound of claim 1 , wherein both R groups are unsubstituted C 1 -C 4 alkyl.
8. The compound of claim 1 , wherein both R groups are methyl.
9. The compound of claim 1 , wherein both R groups are methoxy.
10. The compound of claim 1 , wherein both R groups are methylcarbonyloxy.
11. The compound of claim 1 , wherein both values of z are 1.
12. The compound of claim 1 , wherein both values of z are 2.
13. A compound of claim 1 selected from the group consisting of:
and a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition comprising a compound of claim 1
and a pharmaceutically acceptable carrier.
15. The pharmaceutical composition of claim 14 , wherein the composition is adapted for parenteral administration.
16. The pharmaceutical composition of claim 15 , wherein the composition provides a duration of release of naltrexone of about 9 weeks following parenteral administration.
17. The pharmaceutical composition of claim 15 , wherein the composition provides a duration of release of naltrexone of about 13 weeks following parenteral administration.
18. The pharmaceutical composition of claim 15 , wherein the parenteral administration is an intramuscular injection.